<?xml version="1.0" encoding="UTF-8"?>
<p>Perhaps remdesivir, a broad-spectrum antiviral drug, shows the most promise for human coronavirus infections. It has superior activity against MERS-CoV in vitro, when tested against existing antivirals. In mouse models, when used for prophylaxis and treatment, it showed improved pulmonary lung function values, reduced lung viral loads and lung pathology findings on post-mortem examination [
 <xref ref-type="bibr" rid="CR3">3</xref>]. The authors concluded “our work suggests that remdesivir may improve disease outcomes in coronavirus patients, serve to protect health care workers in area with endemic MERS-CoV and prove valuable in preventing future epidemics ” [
 <xref ref-type="bibr" rid="CR3">3</xref>].
</p>
